Researchers reported a 100% disease control rate in 27 evaluable patients with KRASG12C-mutant pancreatic ductal adenocarcinoma and other gastrointestinal tumors, not including colorectal cancer, who received adagrasib monotherapy. These preliminary data come from the phase II portion of the KRYSTAL-1 study, which is assessing the safety and efficacy of the KRASG12C inhibitor.

You do not currently have access to this content.